Is MAXIMUS, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for MAXIMUS, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued at this time. Key valuation ratios include a P/E ratio of 13, an EV to EBITDA of 8.13, and a PEG ratio of 0.35, which suggest that the stock is reasonably priced relative to its earnings growth potential.
In comparison to its peers, MAXIMUS, Inc. has a P/E ratio of 15.70, which is lower than Medpace Holdings, Inc. at 33.13 and higher than ADT, Inc. at 10.02. Additionally, Genpact Ltd. has a P/E ratio of 14.38, indicating that MAXIMUS is positioned competitively within its industry. Notably, the company's stock has underperformed against the S&P 500 over the past year, with a return of -5.29% compared to the index's 14.08%, which reinforces the notion of its fair valuation amidst broader market performance.